Manulife Financial Corporation research snapshot
MFC AI stock analysis as of the August 2, 2026 data cutoff reads Manulife Financial as a diversified insurer and wealth manager with an Asia growth franchise, Canadian scale, John Hancock operations in the United States, and global asset management. The stock was at $44.44 at the July 31, 2026 close with a market capitalization near $74.07 billion, re-verified during this full refresh as $44.44 times 1.67 billion shares with a 0.20% deviation. Q1 2026, reported May 13, 2026, delivered core earnings of C$1.836 billion up 8% on a constant-exchange-rate basis, core EPS of C$1.06 up 11%, net income attributed to shareholders of C$1.147 billion up 149%, new business CSM up 16%, and a 16.5% core ROE with a 136% LICAT ratio, while Global WAM recorded C$4.4 billion of net outflows. FY2025 core earnings were a record C$7.521 billion with a 10.2% dividend increase and 54.4 million shares repurchased. The stock is up about 44.8% over 52 weeks, trades near its 52-week high of $44.89, sits above its 20-day, 50-day, 100-day, and 200-day moving averages, and carries roughly a 17.85x trailing PE and 13.43x forward multiple. Offsetting this is an aggregate analyst target reported below the current price, persistent Global WAM outflows, U.S. core earnings pressure, market-experience sensitivity, and a premium to book value. The page presents scenario ranges, not a certain prediction, and is for information only.
Current price
$44.44
Market cap
$74.07 billion
AI score
72 / 100
Rating
Diversified life insurer and wealth manager with strong Asia growth and capital returns, now trading near a 52-week high with a premium valuation
Trend status
Bullish trend above the 20-day, 50-day, 100-day, and 200-day moving averages
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Manulife earns from life and health insurance, annuities, retirement products, wealth and asset management, banking, and investment products across Asia, Canada, the United States, and global institutional channels, with TTM revenue near C$62.5 billion on the StockAnalysis.com income statement. | High |
| Moat | The moat rests on trusted brands including Manulife and John Hancock, insurance licenses, distribution relationships, actuarial and investment capabilities, long-duration policyholder relationships, scale, data, and regulatory infrastructure. These advantages are meaningful but do not remove price competition, regulation, investment risk, or lapse risk. | Medium-high |
| Management | CEO Phil Witherington and CFO Colin Simpson delivered record FY2025 core earnings of C$7.521 billion, a 10.2% dividend increase, 54.4 million shares repurchased, an India entry with Mahindra, the Comvest and Schroders Indonesia acquisitions, and an expanded Microsoft AI partnership, while keeping LICAT at 136% and core ROE at 16.5%. | Medium-high |
| Financial trend | Q1 2026 core earnings were C$1.836 billion up 8% CER, core EPS rose 11% to C$1.06, net income attributed to shareholders rose 149% to C$1.147 billion, new business CSM rose 16%, and the CSM balance reached C$25.589 billion, while FY2025 core earnings were a record C$7.521 billion, offset by C$4.4 billion of Q1 Global WAM net outflows and a 4% decline in U.S. core earnings. | High |
| Valuation | At about 17.85x trailing EPS and 13.43x forward earnings computed from the $44.44 price, with a 3.00% dividend yield and roughly 2x book value per share, the market already prices in continued execution near a 52-week high. | Medium |
| Technical trend | MFC closed at $44.44 on July 31, 2026, above its 20-day, 50-day, 100-day, and 200-day moving averages, with 14-day RSI near 68.84 and 14-day ADX near 36.78 confirming a trend move, just below the 52-week high of $44.89. | Medium |
| Risk level | Key risks are persistent Global WAM outflows, U.S. core earnings pressure, market and alternative-asset experience losses, mortality and morbidity claims, lapse behavior, capital requirements, currency, Asia execution, and valuation compression after a 44.8% 52-week gain. | Medium-high |
| AI confidence | High for descriptive facts and cross-checked math that matched across StockAnalysis.com, SEC EDGAR XBRL, and the Manulife earnings releases. Lower for forward return estimates because investment markets, insurance experience, flows, and multiples are uncertain. | High data confidence |
| Investment certainty | Medium certainty. The page gives a research framework and scenario ranges, not a buy or sell instruction, and the reported analyst aggregate target below spot is a signal that upside is not guaranteed. | Medium |
MFC AI stock forecast
The MFC AI stock forecast uses scenario math around the July 31, 2026 close of $44.44 and a forward EPS basis near $3.31 implied by the 13.43x forward multiple, audited with financial_rigor.py. The three-scenario framework produced a bearish area near $36 to $41, a base area near $50 to $57, and a bullish area near $66 to $74 before dividends, using forward EPS growth of about 2%, 6%, and 10% and exit multiples of 11x, 14x, and 17x over three years. A trailing-EPS model produces lower values because trailing GAAP earnings include market experience. These are scenarios, not price commitments.
$66 to $74
More likely if forward EPS compounds near 10%, Asia insurance sales and CSM growth stay strong, Global WAM flows turn positive, claims and investment experience are favorable, capital stays strong, and investors pay about 16x to 17x forward earnings.
$50 to $57
More likely if EPS grows near 6%, Asia and wealth-management gains offset continued market variability and mixed Global WAM flows, dividends and buybacks continue, and the market values MFC near 14x forward earnings.
$36 to $41
More likely if investment markets or alternative assets weaken, claims or lapse experience deteriorates, Global WAM outflows persist, Asia growth slows, capital becomes constrained, or the multiple contracts toward 11x forward earnings, a zone near the reported aggregate analyst target.
MFC AI technical analysis
MFC AI technical analysis is bullish as of the August 2, 2026 data cutoff. The stock closed at $44.44 on July 31, 2026, above its 20-day moving average near $42.81, its 50-day near $40.83, its 100-day near $38.82, and its 200-day near $37.09, with 14-day RSI near 68.84 and 14-day ADX near 36.78 confirming a trend. The 52-week high of $44.89 sits just overhead as the next resistance.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $44.44 | StockAnalysis.com real-time quote at the July 31, 2026 close; market cap math uses 1.67 billion shares outstanding. |
| Near support | $42.80 to $42.90 | Barchart reported the 20-day moving average near $42.81 as of July 31, 2026, a natural first pullback support zone. |
| Next support | $40.80 to $41.00 | The 50-day moving average was near $40.83 on Barchart and StockAnalysis.com, a key medium-term trend level. |
| Broader support | $38.80 to $39.00 | The 100-day moving average was near $38.82 and the 200-day near $37.09, forming a deeper support cluster. |
| Near resistance | $44.89 | The 52-week high of $44.89, reached on the July 31, 2026 session, is the immediate overhead level. |
| 50-day moving average | $40.83 | Barchart and StockAnalysis.com both reported the 50-day moving average near $40.83 on July 31, 2026. |
| 200-day moving average | $37.09 | Barchart and StockAnalysis.com both reported the 200-day trend line near $37.09, well below price and confirming the longer uptrend. |
| 100-day moving average | $38.82 | Barchart reported the 100-day moving average near $38.82 on July 31, 2026, below price and confirming the medium-term uptrend. |
| Momentum | RSI near 69, Stochastic near 88 | 14-day RSI was near 68.84, elevated but not yet overbought, and 14-day Stochastic %K near 87.67 on Barchart, so a new high would need to hold rather than fade. |
| Volume | About 1.4 million average shares | Barchart listed 20-day average volume near 1.56 million shares and StockAnalysis.com near 1.36 million on July 31, 2026, so breakout quality should be checked against live volume. |
| Volatility | Moderate, rising near earnings | Barchart reported 14-day historical volatility near 19.85% and a 14-day ATR near $0.69, with beta at 0.78, so position sizing should account for moves around the August 5, 2026 earnings date. |
| Invalidation | Close below $42.80, then $40.80 | A decisive close below the 20-day moving average near $42.81 would weaken the short-term uptrend; a close below the 50-day near $40.83 would turn the medium-term trend neutral. |
MFC AI trading strategy
The MFC AI trading strategy is a rules-based research framework for trading and watching the insurer. It is not personal advice and should be paired with fresh chart data, filings, position sizing, and a defined invalidation level, especially with Q2 2026 results due August 5, 2026.
Watch whether MFC holds above the 20-day moving average near $42.80 and clears the $44.89 52-week high on above-average volume, while Q2 results confirm core-earnings growth, insurance sales, CSM growth, capital strength, and improving Global WAM flows.
A daily close below the 20-day moving average or a failed attempt at the 52-week high should trigger a stop and review, especially if flows or U.S. earnings weaken.
If MFC retraces toward the $40.80 to $42.90 support cluster without deterioration in core earnings, claims, CSM, LICAT, or asset-management flows, compare the updated price with book value, sustainable EPS, dividend policy, buybacks, and investment-market conditions.
Do not assume a lower insurer share price is value when capital markets, alternative-asset marks, claims, lapses, or capital requirements are worsening.
Track core earnings and EPS, net income, core ROE, LICAT, book value, new business CSM, APE sales, Asia and Global WAM segment trends, net flows, remittances, dividends, buybacks, and the August 5, 2026 Q2 results.
Position sizing should reflect financial-market sensitivity, long-duration insurance liabilities, foreign exchange, regulation, and the possibility that reported earnings differ from core earnings.
Investment research summary
Customers pay Manulife to protect income and health risks, save for retirement, invest assets, obtain wealth advice, manage benefits, and access banking and retirement products. The company earns fees, insurance margins, and investment income across Asia, Canada, the United States, and institutional asset management.
Manulife has regulated licenses, brands including Manulife and John Hancock, distribution relationships, policyholder trust, actuarial and investment capabilities, long-lived customer relationships, data, and scale. These advantages are meaningful but do not remove price competition, regulation, investment risk, or lapse risk.
The thesis can fail if markets or alternative assets underperform, claims rise, policyholder lapse behavior changes, Global WAM outflows persist, Asia growth slows, U.S. core earnings keep falling, capital requirements rise, acquisitions disappoint, cyber or conduct events damage trust, or foreign exchange reduces reported results.
Phil Witherington and the leadership team are responsible for growth in insurance and wealth, disciplined expense and capital allocation, underwriting and investment controls, distribution productivity, and shareholder returns. The record is strong so far, and the test is sustained value creation through a full market and insurance cycle.
Ageing populations, retirement savings, protection needs, health and longevity products, Asian wealth growth, and the AI transformation of insurance distribution and operations are durable demand drivers. Insurance and asset management remain regulated, competitive, capital intensive, and exposed to markets, rates, claims, and client flows.
At about 17.85x trailing EPS, 13.43x forward earnings, and near 2x book value per share, MFC is not priced as a distressed insurer and trades near a 52-week high. Margin of safety improves if price falls while core earnings, capital, claims, investment quality, CSM growth, and distributions remain intact, or if the multiple compresses to lower levels.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| MFC price | $44.44 at the July 31, 2026 close | StockAnalysis.com real-time quote | August 2, 2026 |
| Market capitalization | $74.07 billion, computed as $44.44 x 1.67 billion shares outstanding with a 0.20% deviation | StockAnalysis.com quote and share statistics | August 2, 2026 |
| Shares outstanding | 1.67 billion shares, down 3.91% year over year, with a 3.91% buyback yield | StockAnalysis.com statistics | August 2, 2026 |
| Q1 2026 results | C$1.836 billion core earnings up 8% CER, C$1.06 core EPS up 11%, C$1.147 billion net income attributed to shareholders up 149%, 16.5% core ROE, 136% LICAT, new business CSM up 16%, APE sales up 7% | Manulife Q1 2026 press release | May 13, 2026 |
| Q1 2026 segment results | Asia core earnings up 22% and NBV up 15%, Canada core earnings down 6%, U.S. core earnings down 4%, Global WAM core earnings up 2% with a 29.0% core EBITDA margin and C$4.4 billion net outflows | Manulife Q1 2026 press release | May 13, 2026 |
| CSM balance | CSM net of NCI of C$25.589 billion at March 31, 2026, up C$620 million in the quarter with 11% annualized organic growth, and post-tax CSM net of NCI of C$21.255 billion | Manulife Q1 2026 press release | May 13, 2026 |
| FY2025 results | Record core earnings of C$7.521 billion up 3% CER, net income attributed to shareholders of C$5.572 billion, C$4.21 core EPS up 8%, C$3.07 EPS, 16.5% core ROE, 136% LICAT, C$6.4 billion remittances, 54.4 million shares repurchased for C$2.4 billion, 10.2% dividend increase, and a new NCIB of up to about 2.5% of shares | Manulife FY2025 press release | February 11, 2026 |
| Book value | Book value per common share of C$26.30 at March 31, 2026 and adjusted book value per common share of C$39.01, with a 22.5% financial leverage ratio | Manulife Q1 2026 press release | May 13, 2026 |
| Balance sheet cash and borrowings | Cash and cash equivalents of C$26.703 billion and total borrowings of C$7.685 billion at December 31, 2025, matching SEC EDGAR XBRL exactly | StockAnalysis.com balance sheet and SEC EDGAR XBRL | August 2, 2026 |
| Total assets and total equity | Total assets of C$1,025.433 billion and common shareholders equity of C$50.121 billion at December 31, 2025, with total equity of C$52.488 billion matching SEC EDGAR XBRL | StockAnalysis.com balance sheet and SEC EDGAR XBRL | August 2, 2026 |
| Valuation check | 17.49x trailing PE, 13.43x forward PE, 3.23x sales, 1.95x book value, 12.56% ROE, 3.00% dividend yield, and a 53.52% payout ratio | StockAnalysis.com statistics | August 2, 2026 |
| Valuation arithmetic cross-check | financial_rigor.py computed 17.85x trailing PE, 2.12x price-to-book, and 2.99% dividend yield from the $44.44 close, $2.49 trailing EPS, $21.00 book value per share, and $1.33 dividend, matching the reported ratios within normal aggregator deviation | StockAnalysis.com statistics and Pineify financial_rigor.py | August 2, 2026 |
| Analyst consensus | Buy with an average price target of $35.72 across 15 analysts, reported 19.62% below the current price, with recent individual updates in the same source set including Jefferies to $50, BMO to $48, Barclays to $56, and Scotiabank to $44 | StockAnalysis.com forecast | August 2, 2026 |
| Analyst rating mix, July 2026 | 6 Strong Buy, 4 Buy, 3 Hold, 2 Sell, and 0 Strong Sell out of 15 analysts | StockAnalysis.com forecast recommendation trends | August 2, 2026 |
| Dividend | $1.33 annual dividend, 3.00% yield, 53.52% payout, 11.41% one-year dividend growth, 10 years of growth, and ex-dividend date May 29, 2026 | StockAnalysis.com dividends | August 2, 2026 |
| Short interest | 6.01 million shares short, 0.36% of shares outstanding, and 3.26 days to cover | StockAnalysis.com statistics | August 2, 2026 |
| Technical snapshot | 20-day SMA near $42.81, 50-day SMA near $40.83, 100-day SMA near $38.82, 200-day SMA near $37.09, 14-day RSI near 68.84, 14-day ADX near 36.78, 14-day historical volatility near 19.85%, and 5-year beta of 0.78 | Barchart and StockAnalysis.com technical snapshots | August 2, 2026 |
| Recent price history | MFC closed at $44.44 on July 31, 2026, up from about $41.09 on July 8 and $38.50 in early June 2026, with a 44.76% 52-week gain and a 52-week range of $29.70 to $44.89 | StockAnalysis.com price history | August 2, 2026 |
| Earnings date | Q2 2026 results scheduled for August 5, 2026, after market close | StockAnalysis.com quote and Manulife press release | August 2, 2026 |
| FY2025 financial trend | FY2025 revenue of C$62.306 billion and net income to common shareholders of C$5.251 billion on the StockAnalysis.com income statement, with 2025 APE sales up 14%, new business CSM up 28%, and NBV up 18% per Manulife | StockAnalysis.com income statement and Manulife FY2025 press release | August 2, 2026 |
| Source limitation | IFRS 17 insurance revenue is not reliably comparable across aggregators: StockAnalysis.com reports FY2025 revenue of C$62.306 billion on the income statement but C$30.98 billion in its standardized overview and forecast views. This page relies on Manulife core earnings, CSM, capital, and segment disclosures as primary and presents the aggregator revenue with that caveat. | StockAnalysis.com financials and forecast; Manulife filings | August 2, 2026 |
This MFC AI stock analysis page is an informational research tool only. It is not investment advice, financial planning, a recommendation, or a guarantee of future performance. Forecast scenarios are based on available public data and simplified assumptions as of the stated cutoff date, and they may be wrong, incomplete, or outdated after new earnings, market moves, or macro conditions. Q2 2026 results are scheduled for August 5, 2026.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
